Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $205.0 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback